- A
dopamine reuptake inhibitor (DRI) is a
class of drug
which acts as a
reuptake inhibitor of the
monoamine neurotransmitter dopamine by
blocking the action...
-
Laura Rosenthal;
Jacqueline Burchum (17
February 2017). Lehne's
Pharmacotherapeutics for
Advanced Practice Providers - E-Book.
Elsevier Health Sciences...
- J,
Zernig G (1995). "Methoclocinnamox: A μ
Partial Agonist With
Pharmacotherapeutic Potential for
Heroin Abuse". In
National Institute on Drug Abuse...
- S2CID 39192378.
Lyonga Ngonge A,
Nyange C,
Ghali JK (February 2024). "Novel
pharmacotherapeutic options for the
treatment of
postural orthostatic tachycardia syndrome"...
-
agonist hallucinogen:
Pharmacology and
potential template for
novel pharmacotherapeutic agents in
neuropsychiatric disorders".
Frontiers in Pharmacology...
-
Specific phobia is an
anxiety disorder,
characterized by an extreme, unreasonable, and
irrational fear ****ociated with a
specific object, situation, or...
-
Albuquerque R, et al. (March 2021). "WWOM VII:
Effectiveness of
systemic pharmacotherapeutic interventions in the
management of BMS: A
systematic review and meta-analysis"...
-
Index 2003, "Morphine" and "Hydromorphone" PHA 4220 –
Neurology Pharmacotherapeutics Archived 16 July 2007 at the
Wayback Machine "Hydromorphone Hydrochloride"...
-
traditional herbo-metallic
preparations concluded that the long-term
pharmacotherapeutic and in-depth
toxicity studies of
these preparations are lacking....
- S2CID 36312234.
Highlander P, Shaw GP (February 2010). "Current
pharmacotherapeutic concepts for the
treatment of
cardiovascular disease in diabetics"...
